Valeant Pharmaceuticals News
Most Popular Valeant Pharmaceuticals Story
Valeant buys Dow in $285M deal
Valeant Pharmaceuticals will beef up its presence in the dermatology field with today's deal to buy Dow Pharmaceutical Sciences for $285 million in cash. The buyout gives Valeant control of the... Read more...
Latest Headlines
- December 10, 2008
- November 14, 2008
- September 17, 2008
- August 28, 2008
- May 2, 2008
- December 21, 2006
- December 13, 2006
- September 11, 2006
- June 14, 2006
- May 15, 2006
- April 3, 2006
- March 20, 2006
- November 28, 2005
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
